This trial is shared by:
When speaking with your doctor refer to the National Clinical Trial (NCT) identifier number: NCT05242822
Kinnate Biopharma Inc. (the study sponsor) is evaluating the efficacy and safety of KIN-3248 (the study drug) in adults with advanced cancer (solid tumors) who have an FGFR2 and/or FGFR3 mutation. FGFR mutations are found in bladder cancers, cholangiocarcinoma, and other cancers. To find out if you have an FGFR mutation, talk with your doctor about ordering biomarker testing or tumor profiling.
This study (also called a clinical trial) will include adults from around the world with advanced solid tumors who have FGFR2 and/or FGFR3 mutations. For this study, participants will take the study drug every day orally (by mouth) and will visit their study site regularly. The sponsor will provide travel support and arrangements to the study site for the participant and one caregiver during participation in the study.
Visit the National Institutes of Health (NIH) clinical trial website for detailed information by using the National Clinical Trial (NCT) identifier number to search for this study: NCT05242822 (ClinicalTrials.gov)
KIN-3248 (study drug) is a type of cancer drug known as a targeted therapy. The purpose of targeted therapies is to aim at specific parts of cancer cells, such as genes that have changed (mutated), to stop the cancer cells from growing or spreading. For some cancers, targeted therapies may work better than other available treatments.
This study will be conducted in 2 parts. The main goals in each part are:
To learn more about the safety and tolerability of the study drug (whether the participants have any medical issues during treatment and, if so, what types of medical issues and how severe they are). The results of Part A will help determine the dose or doses participants take in Part B.
To learn how each participant’s cancer responds to the study drug.
See if you are eligible
If you are interested in participating in this study, you will need to visit a clinical study site. A doctor will explain the study to you. If you agree to participate, the doctors and study staff will perform an evaluation to make sure you are eligible.
If you decide to participate this study, you will receive the study drug until:
Full details about the study, visits, and examinations will be discussed with you before you decide to participate in the study.
If you are interested in learning more about this study, take the following steps:
NCT identifier number: NCT05242822
Kinnate Biopharma will cover travel expenses related to the study visits for the participant and one caregiver at select sites that participate in our travel support program. Examples of expenses:
Additional information on travel support will be provided by the site staff should you decide to participate.
You will need to travel to one of the study clinics taking part in this clinical trial. Sites are located in:
See if you are eligible